JUPITER data justify statin use against diabetes concerns
This article was originally published in Scrip
Concerns over statin use increasing the risk of developing diabetes should not prevent their use even in patients at high risk of developing the metabolic disease, suggests a new analysis of the JUPITER study of AstraZeneca's Crestor (rosuvastatin). The cardiovascular and mortality benefits of statin therapy exceed the diabetes hazard, the researchers found, allaying fears over their use, particularly in primary prevention.
You may also be interested in...
A Phase III rare-disease hit for Sanofi marks the first of a number of orphan drug read-outs expected in the coming year.
Philadelphia is due to host the American Heart Association (AHA) meeting for the first time from 16-18 November, with the conference taking place in its condensed three-day format for just the second time. Scrip takes a look at the expected highlights.
Shares plummet as ObsEva announces it is discontinuing its IVF program for nolasiban after disappointing Phase III data from a European confirmatory study.